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Abstract
 
Objective
 
To study the prevalence and risk factors of depressive symptoms, comparing subjects with normal glucose
metabolism (NGM), impaired glucose metabolism (IGM) or Type 2 diabetes mellitus (DM2).
 
Research design and methods
 
Cross-sectional data from a population-based cohort study conducted among 550 residents
(276 men and 274 women) of the Hoorn region, the Netherlands. Levels of depressive symptoms were measured using
the Centre for Epidemiologic Studies Depression Scale (CES-D score 
 
≥
 
 16). Glucose metabolism status was determined
by means of fasting and post-load glucose levels.
 
Results
 
The prevalence of depressive symptoms in men with NGM, IGM and DM2 was 7.7, 7.0 and 15.0% (
 
P
 
 
 
=
 
 0.19)
and for women 7.7, 23.1 and 19.7% (
 
P
 
 < 0.01), respectively. Depression was significantly more common in women with
IGM [odds ratio (OR) 
 
=
 
 3.60, 95% confidence interval (CI) 
 
=
 
 1.57 to 8.28] and women with DM2 (OR 
 
=
 
 3.18, 95%
CI 
 
=
 
 1.31 to 7.74). In men, depression was not associated with IGM (OR 
 
=
 
 0.90, 95% CI 
 
=
 
 0.32 to 2.57) and non-significantly
more common in DM2 (OR 
 
=
 
 2.04, 95% CI 
 
=
 
 0.75 to 5.49). Adjustment for cardiovascular risk factors, cardiovascular
disease and diabetes symptoms reduced the strength of these associations.
 
Conclusions
 
Depressive symptoms are more common in women with IGM, but not men. Adjustment for cardiovascular
risk factors, cardiovascular disease and diabetes symptoms partially attenuated these associations, suggesting that these
variables could be intermediate factors.
Diabet. Med. 25, 843–849 (2008)
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Introduction
 
Diabetes and depression are both common diseases. There are
currently more than 171 million people with diabetes, mostly
Type 2 diabetes mellitus (DM2), worldwide [2]. It is estimated
that this number will rise to 366 million in 2030 [1,2]. An
estimated 121 million people currently suffer from depression
and about 6% of men and 10% of women will experience a
depressive episode in any given year [3]. Evidence from the
past decades strongly suggests that diabetes and depression are
associated. Approximately 10–15% of patients with diabetes
mellitus meet criteria for co-morbid major depression [4,5].
Interestingly, depression is also a risk factor for development
of diabetes mellitus [6,7]. Knol 
 
et al
 
. concluded that non-
diabetic adults with depression have a 30% increased risk
for DM2 [8]. Moreover, depression also contributes to poor
self-care and adherence to medical treatment, higher symptom
burden [9], higher glycated haemoglobin (HbA
 
1c
 
) [10], more
diabetes complications [11,12] and increased healthcare use
and costs in patients with diabetes [13,14].
In concert with the increasing number of people with diabetes,
the number of people with impaired glucose metabolism
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(pre-diabetes) is also rising rapidly [15]. Given the close association
of depression with DM2 and the rising numbers of both DM2 and
people with impaired glucose metabolism, it is logical to study
whether this association also exists in persons with pre-diabetes.
This could shed light on the underlying mechanisms explaining
the observed association between depression and metabolic
abnormalities. Until recently, the prevalence of depression among
different groups of glucose metabolism was not known.
Knol 
 
et al
 
. were the first to study the prevalence of depression
in people with impaired fasting glucose [16]. They found that
impaired fasting glucose was not associated with depressive
symptoms, while diagnosed DM2 was associated with an
increased prevalence of depressive symptoms. The authors
stated important limitations such as the use of self-report
to define diagnosis of DM2 and the possible lack of genera-
lizabillity because of the relatively young age (mean age
39.4 years) of the study population. Knol 
 
et al
 
. did not report
the association between groups of different glucose metabolism
and depression for men and women separately. There is
evidence that this association is stronger for women with DM2
compared with men and it is hypothesized that this may be
because of differences in oestrogen levels [17].
The actual prevalence and risk factors of depressive symptoms
in normal glucose metabolism subjects, impaired glucose
metabolism (pre-diabetes) subjects and patients with DM2 for
both men and women separately, is currently unknown. Such
knowledge is relevant from a clinical perspective as pre-diabetes
is increasingly common. Moreover, depression is an established
risk factor for cardiovascular disease.
We therefore analysed cross-sectional data from the Hoorn
Study, a population-based cohort study, to investigate the
prevalence and risk factors of depression in a group of elderly
adults, comparing subjects with normal glucose metabolism
with subjects with impaired glucose metabolism (pre-diabetes) and
patients with DM2 and analysing men and women separately.
 
Research design and methods
 
Subjects
 
The Hoorn Study is a population-based cohort study on DM2
in the general Dutch population that started in 1989 and has
been described in detail previously [18]. In summary, it consisted
of 2484 men and women aged 50–75 years at baseline, selected
from the population register of the middle-sized Dutch town of
Hoorn. In 2000–2001, a third examination was performed of
surviving participants who gave their permission to be re-
contacted. We invited all participants who had diabetes, as
determined by a 75-g oral glucose tolerance test (OGTT) or by
diabetes treatment (
 
n
 
 
 
=
 
 176) at the second examination of the
entire cohort in 1996–1998 [19]. We also invited random
samples of participants who had normal glucose metabolism
(
 
n
 
 
 
=
 
 705) or impaired glucose metabolism (
 
n
 
 
 
=
 
 193) in 1996–
1998. Of 1074 individuals invited, 648 persons (60.3%)
participated. The main reasons for not participating in the
2000–2001 follow-up examination are described elsewhere
[20]. For the present study, cross-sectional data of the 2000–
2001 follow-up examination were analysed. Of the 648
participants, 84 individuals were excluded because of missing
symptoms of depression data. Another 14 individuals were
excluded because glucose metabolism data were incomplete.
Therefore, our final study cohort consisted of 550 subjects; 276
men and 274 women (Fig. 1). The study protocol was approved
by the Ethical Review Committee of the VU University Medical
Center and all participants gave written informed consent.
 
Depressive symptoms
 
Levels of depressive symptoms were measured using the 20-item
Centre for Epidemiologic Studies Depression Scale (CES-D
FIGURE 1 Flow chart of the study population at baseline and follow-up 
examinations. CES-D, Centre for Epidemiologic Studies Depression Scale.
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score 
 
≥
 
 16) [21]. The Dutch translation of this instrument has
good psychometric properties and satisfactory criterion validity
[22]. The overlap between depression and symptoms of physical
illness appeared to be minimal in several studies. The CES-D
measures the frequency of symptoms of depression over the
past 7 days. The CES-D total score can range from 0 to 60. The
generally used cut-off score of 16 and above was used to identify
respondents with clinically significant levels of depression
[22].
 
Demographic and cardiovascular variables
 
Data were collected during the medical examination that was
carried out at the Diabetes Research Centre in Hoorn. Information
about age, sex, smoking and education level (low vs. middle
and high level) was assessed by means of a questionnaire.
Participants were not aware of their metabolic status prior to
completing either the CES-D or the Type 2 Diabetes Symptom
Checklist. Waist circumference was measured at the level midway
between the lowest rib margin and the iliac crest. Fasting and 2-h
post-load plasma glucose were measured with the hexokinase
method (Roche Diagnostics, Mannheim, Germany). Glucose
metabolism status was defined according to the World Health
Organization (WHO) 1999 criteria, i.e. fasting plasma glucose
 
≥
 
 7.0 mmol/l on two separate occasions or a plasma glucose
level 
 
≥
 
 11.1 mmol/l 2 h after the glucose load [23]. HbA
 
1c
 
 was
determined by ion-exchange high-performance liquid chroma-
tography with Modular Diabetes Monitoring System (Bio-Rad,
Veenedaal, the Netherlands). Serum total cholesterol, high-density
lipoprotein (HDL) cholesterol and triglycerides were measured
by enzymatic techniques (Boeringer-Mannheim, Mannheim,
Germany).
Systolic and diastolic blood pressure were determined at the
right upper arm, after 5 min rest in seated participants, with a
random-zero sphygmomanometer (Hawksley-Gelma, Lancing,
UK). Blood pressure was calculated as the mean of two meas-
urements. Individuals were considered to be hypertensive if
they had a diastolic blood pressure 
 
≥
 
 90 mmHg and/or a systolic
blood pressure 
 
≥
 
 140 mmHg and/or they were taking anti-
hypertensive medication. Carotid intima-media thickness (IMT)
was determined by ultrasonography, using previously described
techniques [24]. Subjects were classified as having albuminuria
if they had an albumin : creatinine ratio > 2.0 mg/mmol. Ischaemic
heart disease was defined as the presence of Minnesota codes
1-1, 1-2, 1-3, 4-1, 4-2, 4-3, 5-1, 5-3 or 7-1, respectively, on the
electrocardiogram recording.
 
Diabetes symptoms
 
People with pre-diabetes may experience symptoms of diabetes.
This may contribute to the development of depression. To
measure diabetes symptom distress, we used the revised version
of the Type 2 Diabetes Symptom Checklist [25], which refers to
the month preceding the visit. The presence of diabetes-related
symptoms is measured as Yes/No and, if the respondent answers
Yes, the perceived burden was scored on a 5-point Likert-scale
from 0 (‘not at all’) to 4 (‘extremely’). The Type 2 Diabetes
Symptom Checklist consists of 34 symptom items covering
eight dimensions: hyperglycaemic (four items), hypoglycaemic
(three items), polyneuropathic pain (four items), polyneuro-
pathic sensory (six items), psychological fatigue (four items),
psychological cognitive distress (four items), cardiovascular
(four items) and ophthalmological (five items) symptoms. The
eight sub-scale scores are calculated by summating the item
scores, divided by the number of items of that dimension. The
Type 2 Diabetes Symptom Checklist total score is calculated by
summation of all item scores divided by 34. Higher scores
indicate more symptom distress. The scales of the Type 2 Diabetes
Symptom Checklist appeared to have satisfactory reliability
[26,27].
 
Statistical analysis
 
All analyses were performed separately for men and women
because of the statistically significant effect modification by sex
of the relations under condition. Descriptive data (means,
standard deviation and percentage) of subjects with normal
glucose metabolism, impaired glucose metabolism and DM2
are presented for men and women separately. Differences in
study sample characteristics for the three groups of glucose
metabolism status by sex were examined using analyses of
variance for continuous variables and 
 
χ
 
2
 
-tests for categorical
variables. Next, analyses were carried out to contrast the data
on depressive symptoms (CES-D score 
 
≥
 
 16), comparing subjects
with impaired glucose metabolism or detected DM2 with
normal glucose metabolism subjects. In analyses pertaining to
depressive symptoms, crude and adjusted odds ratios with 95%
confidence intervals were calculated. Logistic regression analyses
were used to study whether depression symptom severity was
significantly associated with demographic variables (age and
low education). Moreover, we were interested in the potential
intermediating effects of cardiovascular diseases, cardiovascular
risk factors and diabetes symptoms on the relationship
between glucose status and depression. Therefore, we tested
whether adjustment for cardiovascular risk factors (triglyc-
erides, HDL cholesterol, total cholesterol, waist circumference,
hypertension and smoking), cardiovascular disease (carotid
IMT, myocardial infarction and ischaemic heart disease) and
diabetes symptoms (hyperglycaemic, cardiovascular, neuro-
pathic pain, sensibility and ophthalmological) changed the
association between glucose status and depression. In these
analyses, we excluded three of the eight diabetes symptoms
dimensions (hypoglycaemic, psychological fatigue and
cognitive distress) from the model (Model 4) because these
scales contain depressive/anxiety/irritability symptoms that
are also used in the depression outcome parameter. For all
statistical testing, we used two-sided hypothesis testing with an
alpha level of < 0.05. Statistical analyses were performed using
the SPSS 11.5 software package for Windows (SPSS Inc., Chicago,
IL, USA).
 
Results
 
Participants
 
Descriptive data (means, standard deviation and percentage)
of the demographic and clinical variables of the subjects with
normal glucose metabolism (NGM), impaired glucose
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metabolism (IGM) or DM2 subjects are presented stratified by
sex in Table 1. There were 550 subjects, 276 men (50.2%) and
274 women, aged 69.5 
 
±
 
 6.3 years (mean 
 
±
 
 
 
SD
 
). Of those, 309
subjects were between 60 and 69 years of age (56.2%), 196
subjects were between 70 to 79 years of age (35.6%) and 45
subjects were between 80 and 87 years old (8.2%). Fasting
plasma glucose, HbA
 
1c
 
, triglycerides, HDL cholesterol, waist
circumference and hypertension in both sexes were significantly
associated with deteriorating glucose metabolism when tested
for a linear trend. Likewise, smoking in men and age and
carotid IMT in women were positively associated with
impaired glucose metabolism status.
 
Prevalence of depressive symptoms
 
The prevalence of depressive symptoms in the whole group
was 12% [men 9.1% (
 
n
 
 
 
=
 
 25) and women 15.0% (
 
n
 
 
 
=
 
 41)].
The prevalence of depressive symptoms in men with NGM,
IGM and DM2 was 7.7, 7.0 and 15.0% (
 
P
 
 
 
=
 
 0.19) and for women
was 7.7, 23.1 and 19.7% (
 
P
 
 < 0.01), respectively (Table 2).
Table 1 Characteristics of the study participants by sex and glucose status
Men Women
NGM IGM DM2 P NGM IGM DM2 P
N 130 86 60     — 130 78 66     —
Age (years) 69.1 ± 5.9 69.1 ± 6.1 70.9 ± 6.4 0.131 68.0 ± 6.0 70.4 ± 5.9 72.1 ± 7.1 < 0.001
Low education (%) 42.3 40.7 32.2 0.408 45.4 57.3 61.3 0.072
Fasting plasma glucose (mmol/l) 5.5 ± 0.4 6.1 ± 0.5 8.0 ± 1.9 < 0.001 5.4 ± 0.4 6.1 ± 0.5 7.9 ± 2.2 < 0.001
HbA1c (%) 5.7 ± 0.4 5.8 ± 0.4 6.8 ± 1.0 < 0.001 5.7 ± 0.4 5.9 ± 0.3 6.8 ± 0.9 < 0.001
Triglycerides (mmol/l) 1.3 ± 0.6 1.5 ± 0.7 1.9 ± 1.0 < 0.001 1.2 ± 0.6 1.6 ± 0.8 1.9 ± 0.9 < 0.001
HDL cholesterol (mmol/l) 1.3 ± 0.4 1.3 ± 0.3 1.1 ± 0.3 < 0.001 1.7 ± 0.4 1.5 ± 0.4 1.4 ± 0.4 < 0.001
Total cholesterol (mmol/l) 5.4 ± 1.0 5.5 ± 1.0 5.2 ± 1.0 0.089 6.1 ± 0.9 6.1 ± 1.1 5.9 ± 1.0 0.343
Waist circumference (cm)  96 ± 9  100 ± 10  102 ± 10 < 0.001  86 ± 10  95 ± 11  98 ± 12 < 0.001
Hypertension (%) 59.2 65.1 88.3 < 0.001 54.6 79.5 92.3 < 0.001
Smoking (%) 22.3 29.1 10.0 0.022 12.3 15.4 10.8 0.693
Carotid IMT (mm) 0.86 ± 0.19 0.89 ± 0.18 0.93 ± 0.19 0.092 0.80 ± 0.15 0.87 ± 0.15 0.91 ± 0.15 < 0.001
Myocardial infarction (%) 10.1 7.1 9.1 0.749 3.1 6.4 6.7 0.422
Ischaemic heart disease (%) 31.8 32.9 38.2 0.696 33.1 39.7 50.0 0.082
Data are %, means ± SD. P = P-values based on one-way ANOVA for continuous variables and χ2-tests for categorical variables.
DM2, Type 2 diabetes mellitus (World Health Organization 1999 criteria); HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; 
IGM, impaired glucose metabolism; IMT, intima-media thickness; NGM, normal glucose metabolism; SD, standard deviation.
Table 2 Prevalence (%) and odds ratios for elevated levels of depressive symptoms (CES-D score ≥ 16) by sex with impaired glucose metabolism or 
Type 2 diabetes subjects compared with normal glucose metabolism subjects
n % (n)
Unadjusted 
OR (95% CI)*
Model 1 
OR (95% CI)†
Model 2 
OR (95% CI)‡
Model 3 
OR (95% CI)§
Model 4 
OR (95% CI)¶
Men NGM 130 7.7 (10) Referent Referent Referent Referent Referent
IGM 86 7.0 (6) 0.90 (0.32–2.57) 0.90 (0.31–2.58) 0.78 (0.26–2.35) 0.83 (0.23–2.95) 0.89 (0.28–2.90)
DM2 60 15.0 (9) 2.04 (0.76–5.49) 1.95 (0.71–5.34) 1.05 (0.32–3.39) 1.26 (0.36–4.43) 1.52 (0.47–4.94)
R2 2% 5% 13.6% 14.3% 25.8%
Women NGM 130 7.7 (10) Referent Referent Referent Referent Referent
IGM 78 23.1 (18) 3.60 (1.57–8.28) 3.04 (1.28–7.21) 2.55 (1.00–6.49) 3.48 (1.35–8.95) 2.21 (0.87–5.60)
DM2 66 19.7 (13) 3.18 (1.31–7.74) 3.18 (1.26–8.02) 2.52 (0.86–7.33) 2.83 (0.93–8.61) 2.76 (1.01–7.50)
R2 7.3% 9.6% 12.6% 13.6% 25.8%
*The unadjusted odds ratios.
†Model 1: adjusted for age and low education.
‡Model 2: adjusted for age, low education and cardiovascular risk factors (triglycerides, HDL cholesterol, total cholesterol, waist circumference, 
hypertension and smoking).
§Model 3: adjusted for age, low education and cardiovascular diseases (carotid intima-media thickness and ischaemic heart disease).
¶Model 4: adjusted for age, low education and diabetes symptoms (hyperglycaemic, cardiovascular, neuropathic pain, sensibility and 
ophthalmological).
CES-D, Centre for Epidemiologic Studies Depression Scale; CI, confidence interval; DM2, Type 2 diabetes mellitus (World Health Organization 
1999 criteria); IGM, impaired glucose metabolism; NGM, normal glucose metabolism; OR, odds ratio.
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Risk factors
 
In the unadjusted logistic regression analysis, the odds for
higher levels of depressive symptoms was three-fold in women
with IGM (OR 
 
=
 
 3.60, 95% CI 
 
=
 
 1.57 to 8.28) or DM2
(OR 
 
=
 
 3.18, 95% CI 
 
=
 
 1.31 to 7.74) (Table 2). In contrast, in
men depression was not associated with IGM (OR 
 
=
 
 0.90,
95% CI 
 
=
 
 0.32 to 2.57), whereas men with DM2 had a
doubled risk for depression (OR 
 
=
 
 2.04, 95% CI 
 
=
 
 0.75 to
5.49), although this was not statistically significant.
In men, the association between DM2 and depressive
symptoms did not substantially change when adjusting for age
and low education (only 4% lower). However, in men with
DM2, the odds ratio dropped considerably after adjusting for
cardiovascular risk factors (Model 2; 48% reduction) or the
presence of cardiovascular disease (Model 3; 38% reduction)
and to a lesser degree after adjustment for diabetes symptoms
(Model 4; 25% reduction). However, this data should be
interpreted with caution because none of the presented odds
ratios for men reached statistical significance.
In women, when adjusting for age and low education
(Model 1), the odds ratios for IGM and DM2 were only
slightly attenuated and remained significant. The odds ratio
for the association between IGM or DM2 and depression
dropped after adjustment for cardiovascular risk factors
(Model 2; 29% reduction in IGM, 21% reduction in DM2),
cardiovascular disease (Model 3; 3% reduction in IGM, 11%
reduction DM2) or diabetes symptoms (Model 4; 39% reduction
in IGM, 13% reduction DM2).
 
Discussion
 
To our knowledge, this is the first population-based study that
determined the prevalence and risks for depressive symptoms
in different groups of glucose metabolism for men and women
separately, using diagnostic criteria for diabetes (i.e. OGTT).
We observed that the prevalence of depressive symptoms was
higher in women with IGM and DM2 compared with NGM.
In men, depressive symptoms were not associated with IGM,
whereas men with DM2 had a doubled risk for depres-
sion, although this was not statistically significant. Interestingly,
adjustment for cardiovascular risk factors, cardiovascular
diseases and diabetes symptoms lowered these odds ratios
considerably, suggesting that these variables could be inter-
mediate factors.
The observation that IGM was not associated with increased
depression in men, in contrast to women with IGM, was
unexpected and is difficult to explain. It is conceivable that the
results are as a result of selection bias, for example, because
male participants with depression were less willing to participate
in the study. Our finding that the prevalence of depressive
symptoms is not higher in men with IGM and diabetes is
consistent with the finding of the Caerphily prospective cohort
study, which showed that insulin resistance was not associated
with depression in middle-aged men [28]. The results in the
men are also consistent with recent results of Knol 
 
et al
 
., who
found that an increased level of depressive symptoms was not
more common in men and women with impaired fasting glucose
[16]. In another study, we found only weak associations
between depressive symptoms and insulin resistance, which
did not differ among different glucose metabolism subgroups
or between men and women [29]. The fact that HbA
 
1c
 
 was
similar in subjects with NGT and IGT speaks against the possi-
bility that hyperglycaemia is responsible for the association
between depressive symptoms and different states of glucose
tolerance. Thus, it could be speculated (while ruling out insulin
resistance and hyperglycaemia) that cardiovascular risk factors
(or factors of the metabolic syndrome) combined with
readiness to report symptoms may be more important for high
depressive symptoms than diabetes-related metabolic variables.
Cardiovascular disease is one of the most common com-
plications of diabetes. The review de Groot 
 
et al
 
. concluded
that cardiovascular disease is associated with an increased risk
for depression [11]. Furthermore, in an earlier study using data
of the Longitudinal Aging Study Amsterdam, we have found
that the prevalence of increased depressive symptoms was not
increased in patients with diabetes only, while it was increased
in diabetes patients who had co-morbid disease, in particular
those with cardiovascular disease [30]. We found only partial
attenuation of the association between glucose metabolism
and depression by cardiovascular disease (or its risk factors)
and diabetes symptoms. We therefore believe that the prevalence
of depression in women with IGM could be related to other,
unmeasured confounders, such as being widowed or the
burden of having other co-morbid disease(s).
The results of the present study, demonstrating partial
attenuation of the association between glucose metabolism
and depression by cardiovascular disease (or its risk factors)
and diabetes symptoms suggest that other mechanisms, in
addition to the burden of disease, might also play a role. Some
plausible alternative mechanisms include, for example, dys-
regulation of the hypothalamic–pituitary–adrenal axis and the
sympathetic nervous system [31–33], sex steroid hormone
levels [34], the role of polyunsaturated fatty acids [35], low
grade inflammation [36,37] or vitamin D deficiency [38–40].
More research is needed with regard to factors underlying
these biological mechanisms.
Several strengths of our study should be emphasized. First,
we used gold-standard assessment to determine glucose
metabolism status by means of fasting glucose and post-load
glucose levels, based on the OGTT and using the WHO 1999
diagnostic criteria. Second, the precise assessment of the
cardiovascular variables, especially carotid IMT determined
by ultrasonography, and myocardial infarction and ischaemic
heart disease defined by using electrocardiogram recording.
Third, the Hoorn Study is conducted in a population-based
cohort. Finally, the outcomes are presented separately for men
and women because of the effect modification by sex.
Our study also has several limitations. First, our results
should be interpreted with caution because of the relative
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small numbers with elevated levels of depression per glucose
group. Second, our depression assessment was based on
self-report, using the CES-D rather than a gold-standard
diagnostic psychiatric interview. However, the CES-D is a
widely used, well-validated measure for depressive symptoms,
particularly suited for large-scale epidemiological studies,
both in the general population and in diabetes patients [41].
Third, the present study has a cross-sectional design, thus we
cannot infer causality between depression and either pre-
diabetes or diabetes. Finally, the present study was limited to
a Dutch Caucasian elderly population. It is not clear whether
the relationship between depression, glucose metabolism and
cardiovascular risk factors is consistent across different racial,
ethnic and age groups.
In conclusion, our study suggests that depressive symptoms
are more common in women with IGM and DM2. In men,
depression was not associated with IGM but non-significantly
increased in DM2. Adjustment for cardiovascular risk factors,
cardiovascular diseases and diabetes symptoms attenuated
these associations, suggesting that these factors could play an
intermediate role in the aetiology of depression in diabetes, or
even explain why depressed people are at increased risk for
DM2. Type 2 diabetes, IGM and depression are increasingly
common conditions [1,2,15]. A high level of depressive
symptoms is not only associated with increased risk for
diabetes and cardiovascular disease, but also with increased
mortality [42–44].
Our findings need to be replicated. Moreover, further
well-designed prospective research is needed: (i) to test whether
depression in IGM is associated with an increased risk for
developing DM2 and cardiovascular disease in women;
(ii) to disentangle the complex causal relationships between
(the onset of) depressive symptoms, glucose metabolism status
and cardiovascular disease; and (iii) to clarify its mechanisms.
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